News and Trends 26 Feb 2018 This Oral Vaccine for Typhoid Raises €8M from International Investors Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […] February 26, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 26 Feb 2018 This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis The use of opioids and non-steroidal anti-inflammatory drugs (NSAIDs) is a massive public health issue. I spoke with Simon Westbrook, CEO of Levicept, whose new approach to pain relief, which is being tested for osteoarthritis, could be a game-changer. Back in September, a couple of weeks into my time at Labiotech, I got the chance […] February 26, 2018 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism and epilepsy. However, one of its drug candidates, GWP42006, has slipped up in a Phase […] February 22, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2018 Early Autism Diagnosis Could be Possible With New Blood and Urine Tests The detection of damaged proteins in blood and urine tests could help to diagnose autism quicker so that children can be given appropriate treatment. Researchers at the University of Warwick have developed new blood and urine tests that detect damaged proteins, which are associated with autism spectrum disorders. The study, published in Molecular Autism, explains how […] February 21, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Organ-on-a-Chip Technology Used to Spot New Hepatitis B Drug Targets Scientists in London are the first in the world to test how pathogens like the hepatitis B virus interact with artificial human organs. Researchers at Imperial College London have used artificial human organs, or organs-on-chips, to replicate the make-up and physiology of the cells in whole organs. The study, published in Nature Communications, shows how the […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors A collaboration between Bicycle Therapeutics and Cancer Research UK has yielded its first peptide to enter clinical trials for solid tumors. Bicycle Therapeutics, the pioneer of the bicyclic peptide platform, has dosed the first patient in a Phase I/IIa trial with its solid tumors candidate, BT1718. The study will test the drug’s safety and efficacy in […] February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 First Functioning Kidney Tissue Generated from Embryonic Stem Cells Researchers at the University of Manchester have used embryonic stem cells to produce kidney tissue that can filter the blood to produce urine, which opens the door to personalized kidney transplants. Scientists at the University of Manchester have generated human kidney tissue from embryonic stem cells for the first time. The research, published in the journal Stem […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2018 Superbugs: Fighting Antibiotic Resistance at the Science Museum An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […] February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2018 Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […] February 7, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […] February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email